Quest Diagnostics Stock-Based Compensation Growth & History (DGX)

Quest Diagnostics's stock-based compensation was $88.0M for fiscal 2025.

View full Quest Diagnostics company overview

Quest Diagnostics annual stock-based compensation history

Quest Diagnostics annual stock-based compensation

Fiscal yearPeriod endedStock-based compensationChangeGrowth
20252025-12-31$88.0M$00.00%
20242024-12-31$88.0M$11.0M+14.29%
20232023-12-31$77.0M$00.00%
20222022-12-31$77.0M−$2.0M−2.53%
20212021-12-31$79.0M−$18.0M−18.56%
20202020-12-31$97.0M$41.0M+73.21%
20192019-12-31$56.0M−$5.0M−8.20%
20182018-12-31$61.0M−$18.0M−22.78%
20172017-12-31$79.0M$10.0M+14.49%
20162016-12-31$69.0M$17.0M+32.69%
20152015-12-31$52.0M$1.0M+1.96%
20142014-12-31$51.0M$23.0M+82.14%
20132013-12-31$28.0M−$22.0M−44.00%
20122012-12-31$50.0M−$22.0M−30.56%
20112011-12-31$72.0M$18.1M+33.51%
20102010-12-31$53.9M−$21.1M−28.15%
20092009-12-31$75.1M$4.5M+6.34%
20082008-12-31$70.6M$13.7M+24.15%
20072007-12-31$56.9M

Quest Diagnostics stock-based compensation trends

Over the last five fiscal years, Quest Diagnostics's stock-based compensation decreased from $97.0M to $88.0M, a change of −$9.0M. The latest reported quarter, Q2 2026, shows $23.0M.

About the metric

What stock-based compensation means

Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.

Calculation and source

SEC-reported stock-based compensation

TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Quest Diagnostics source filings ↗

Community posts

It’s quiet here.

No posts about DGX yet. Start the conversation.

Write the first post